Identification of key regulatory factors for m6A in myasthenia gravis and characteristics of the immune characteristics DOI Creative Commons

Yaoqi Wu,

Xiaoqing Cai,

Yingying Jiao

и другие.

Research Square (Research Square), Год журнала: 2024, Номер unknown

Опубликована: Ноя. 20, 2024

Abstract Myasthenia gravis (MG), a rare autoimmune disorder, presents complex pathogenesis involving various immune molecules. The modification of N6-methyladenosine (m6A) regulates diverse metabolic and immunopathological processes; however, its role in MG remains unclear. We downloaded dataset GSE85452 from the GEO database to identify differentially expressed genes regulated by m6A. Random Forest (RF) method was utilized pivotal regulatory associated with m6A modification. Subsequently, prognostic model crafted confirmed using this gene set. Patients were stratified according expression levels these key genes. Additionally, MG-specific signatures delineated examining cell infiltration patterns their correlations. Further functional annotation, protein-protein interaction mapping, molecular docking analyses performed on biomarkers, leading discovery three that exhibited significant differential within dataset: RBM15, CBLL1, YTHDF1.The random forest algorithm as MG, validated constructing clinical prediction model. Based expression, we divided patients into two groups, revealing distinct varying abundances. also discovered 61 phenotype conducted an in-depth exploration biological roles. YTHDF1 found positively correlated CD56dim natural killer cells, T type 1 helper cells. These stable diagnostic m6A-related markers both validation cohorts. Our findings suggest for MG. analysis may elucidate roles microenvironment

Язык: Английский

CLEC7A Knockdown Alleviates Ischemic Stroke by Inhibiting Pyroptosis and Microglia Activation DOI Creative Commons
Wei Li,

Xiaoli Feng,

Manyu Zhang

и другие.

Journal of Integrative Neuroscience, Год журнала: 2024, Номер 23(12)

Опубликована: Дек. 23, 2024

Background: Ischemic stroke (IS) is the leading cause of mortality worldwide. Herein, we aimed to identify novel biomarkers and explore role C-type lectin domain family 7 member A (CLEC7A) in IS. Methods: Differentially expressed genes (DEGs) were screened using GSE106680, GSE97537, GSE61616 datasets, hub identified through construction protein-protein interaction networks. An IS model was established by middle cerebral artery occlusion reperfusion (MCAO/R). Neural function assessed triphenyl tetrazolium chloride, hematoxylin-eosin, terminal deoxynucleotidyl transferase-mediated nick-end labeling. cell counting kit used detect viability following oxygen-glucose deprivation/reperfusion (OGD/R). Inflammatory factors detected enzyme-linked immunosorbent assay. The mRNA protein expression levels reverse transcription-quantitative polymerase chain reaction western blotting, respectively. Results: Fc fragment Immunoglobulin G (IgG) receptor IIIa (FCGR3A), E (IgE) Ig (FCER1G), Complement component 5a 1 (C5AR1), CLEC7A, Plasminogen activator, urokinase (PLAU), C-C motif chemokine ligand 6 (CCL6) as important genes, from which CLEC7A selected primary subject this study. activation microglia pyroptosis observed MCAO/R with increased interleukin (IL)-1β, IL-18, tumor necrosis factor-α, lactate dehydrogenase. knockdown found promote BV2 cells inhibiting HT22 cells. also decreased infarct volume neurological deficit scores, alleviated injury neuronal apoptosis rats. inhibited microglial model. activator reversed effect on OGD/R-treated Conclusion: a promising biomarker alleviates activation.

Язык: Английский

Процитировано

2
Lipoxin A4 suppresses neutrophil extracellular traps formation through the FPR2-dependent regulation of METTL3 in ischemic stroke DOI Creative Commons
Na Wei, Lu Tan, Jifeng Gu

и другие.

Brain Research Bulletin, Год журнала: 2024, Номер unknown, С. 111178 - 111178

Опубликована: Дек. 1, 2024

Язык: Английский

Процитировано

1
Identification of key regulatory factors for m6A in myasthenia gravis and characteristics of the immune characteristics DOI Creative Commons

Yaoqi Wu,

Xiaoqing Cai,

Yingying Jiao

и другие.

Research Square (Research Square), Год журнала: 2024, Номер unknown

Опубликована: Ноя. 20, 2024

Abstract Myasthenia gravis (MG), a rare autoimmune disorder, presents complex pathogenesis involving various immune molecules. The modification of N6-methyladenosine (m6A) regulates diverse metabolic and immunopathological processes; however, its role in MG remains unclear. We downloaded dataset GSE85452 from the GEO database to identify differentially expressed genes regulated by m6A. Random Forest (RF) method was utilized pivotal regulatory associated with m6A modification. Subsequently, prognostic model crafted confirmed using this gene set. Patients were stratified according expression levels these key genes. Additionally, MG-specific signatures delineated examining cell infiltration patterns their correlations. Further functional annotation, protein-protein interaction mapping, molecular docking analyses performed on biomarkers, leading discovery three that exhibited significant differential within dataset: RBM15, CBLL1, YTHDF1.The random forest algorithm as MG, validated constructing clinical prediction model. Based expression, we divided patients into two groups, revealing distinct varying abundances. also discovered 61 phenotype conducted an in-depth exploration biological roles. YTHDF1 found positively correlated CD56dim natural killer cells, T type 1 helper cells. These stable diagnostic m6A-related markers both validation cohorts. Our findings suggest for MG. analysis may elucidate roles microenvironment

Язык: Английский

Процитировано

0